Product Description: Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].
Applications: COVID-19-immunoregulation
Formula: C25H27N5O2
References: [1]Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1.
CAS Number: 1415823-73-2
Molecular Weight: 429.51
Compound Purity: 99.60
Research Area: Inflammation/Immunology; Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Btk